Invex Therapeutics Ltd
IXC.ASXHealth Care
Biopharmaceuticals.
Market Data
$0.110
-0.1%$8.3M
-100000.0x
$-0.011
0.00%
-0.1%
Latest Earnings
Appendix 4D and Half Year Report
12 February 2026
Invex Therapeutics reported a doubling of its net loss to $716k for the half year ended 31 December 2025, driven by higher administration costs following board changes and ongoing R&D expenses. Despite the increased losses, the company maintained a strong cash position of $4.6M and continued advancing its Exenatide drug development program with positive Alzheimer's disease research results. The company successfully renewed its orphan drug designation in Europe and has a new board in place following significant governance changes. Key points: Strong cash position of $4.6M providing operational runway; Positive Alzheimer's disease research results showing Exenatide reduced neurofilament light chain levels by ~40%; Successful renewal of orphan drug designation in Europe for traumatic brain injury treatment
Recent Announcements
Appendix 4D and Half Year Report
Invex Therapeutics reported a doubling of its net loss to $716k for the half year ended 31 December 2025, driven by higher administration costs following board changes and ongoing R&D expenses. Despite the increased losses, the company maintained a strong cash position of $4.6M and continued advancing its Exenatide drug development program with positive Alzheimer's disease research results. The company successfully renewed its orphan drug designation in Europe and has a new board in place following significant governance changes. Key points: Strong cash position of $4.6M providing operational runway; Positive Alzheimer's disease research results showing Exenatide reduced neurofilament light chain levels by ~40%; Successful renewal of orphan drug designation in Europe for traumatic brain injury treatment
Get real-time alerts for IXC
Receive AI-powered earnings summaries and instant notifications when Invex Therapeutics Ltd releases results.
Register Free